-
Zhang Feng's CRISPR gene-editing drug has been awarded the title of rare pediatric disease again, and is expected to cure β-thalassemia at one time
Time of Update: 2022-06-01
Recommended reading: ASH2019: Sangamo Announces Phase 1/2 Clinical Data for β-Thalassemia, New Gene Editing Cell Therapy Worth Further Exploration Zi's autologous CD34+ hematopoietic stem and progenitor cell injection is an autologous, in vitro gene editing cell therapy research product in clinical development for the treatment of transfusion-dependent β-thalassemia .
-
Zhang Feng's new paper: CRISPR activation screening to discover key proteins of cancer immunotherapy resistance
Time of Update: 2022-04-23
The study found that BCL-2 and B3GNT2 are key drivers of cancer cell resistance to cytotoxic T cells through CRISPRa Screen, and inhibition of these two proteins can enhance the sensitivity of tumor tissue to immunotherapyThis result suggests that a CRISPR-activated screening system can help to elucidate resistance pathways and identify potential targets for cancer immunotherapy .
-
Editas, a company founded by Zhang Feng, initiates a clinical trial of CRISPR-Cas12a gene editing for the treatment of β-thalassemia
Time of Update: 2022-02-24
Recently, Editas Medicine, founded by Professor Feng Zhang, one of the founders of CRISPR gene editing, announced that its IND application for EDIT-301, a gene editing therapy for the treatment of transfusion-dependent beta-thalassemia, has been approved by the FDA and will be launched in 20221 /Phase 2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 in the treatment of transfusion-dependent beta-thalassemia .
-
Editas, founded by Feng Zhang, initiates a clinical trial of CRISPR-Cas12a gene editing to treat β-thalassemia
Time of Update: 2022-01-09
. Recently, Editas Medicine, founded by Professor Zhang Feng, one of the founders of CRISPR gene editing, announced that its IND application for the gene editing therapy EDIT-301 for the treatment of transfusion-dependent β-thalassemia has been approved by the FDA and will be launched in 20221 The Phase 2 clinical trial aims to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 in the treatment of transfusion-dependent β-thalassemia .
-
Zhang Feng's team released CRISPR's new diagnostic system
Time of Update: 2020-12-08
In a paper published recently in the journal , zhang Feng's team at the Broad Institute said they replaced Cas9 in CRISPR/Cas9 with another shear enzyme, Cas13a, extending gene editing tools that were originally targeted to DNA (deoxyribonucleic acid) to a new diagnostic system for targeted RNA (RNA), with sensitivity even high lying to detect individual target nucleic acid molecules, promising revolutionary effects on basic research, infectious disease diagnosis and treatment.
-
NEJM: Zhang Feng's team released the simple CRISPR new crown detection version 2.0 to improve detection sensitivity
Time of Update: 2020-11-02
in the initial STOPCovid testing process, Zhang Feng's team combined the iso-warm PCR step of amplification of RNA numbers with a chemical reaction using Casase to detect specific sequences of the new coronavirus in the same test tube.
-
NEJM: Zhang Feng's team released the simple CRISPR new crown detection version 2.0 to improve detection sensitivity.
Time of Update: 2020-10-10
in the initial STOPCovid testing process, Zhang Feng's team combined the iso-temperature PCR step of amplification of RNA numbers with a chemical reaction using Casase to detect specific sequences of the new coronavirus in the same test tube.
-
CRISPR Key Patent Battle: Zhang Feng's Team Wins.
Time of Update: 2020-09-13
On February 16th the U.S. Patent and Trademark Office announced that the Broad Institute, part of Harvard University and the Massachusetts Institute of Technology, would continue to keep the CRISPR-Cas9 patent, which was granted in 2014, and that the patent battle for the revolutionary gene-editing tool had largely settled.
-
Zhang Feng's latest Cell sub-article: Two new CRISPR-Cas systems.
Time of Update: 2020-09-12
In a recent paper, a team led by Zhang Feng, a well-known CRISPR research pioneer, used computational sequence database mining to discover two class II CRISPR-Cas systems, subtype VI-B, which lack Cas1 and Cas2, contain a single large-scale effect protein Cas13b, and two previously unsolted related proteins: Csx27 and Csx28.
-
Zhang Feng: CRISPR-Cas system classification map.
Time of Update: 2020-09-12
, based on different family of effect proteins, class 1 CRISPR-Cas systems are divided into three types (I, III, IV) and 12 subsypes (see figure below), according to the paper.
study, entitled "Inhibition of CRISPR-Cas9 with Bacteriophage Proteins," scientists found a variety of inhibitors called anti-CRISPRs in Liste bacteria.
-
CRISPR Patent Outcome: Zhang Feng's team provides CRISPR gene editing technology free of charge to academia around the world.
Time of Update: 2020-09-08
in the next few years, more inventors will emerge from the CRISPR field, and more patents will be granted in recognition of everyone who has contributed to advancing CRISPR technology.
-
Zhang Feng, discoverer of GENE editing technology CRISPR, explores the challenges, future applications and development directions of CRISPR!
Time of Update: 2020-08-09
June 9, according to foreign media reports, recently the Atlantic Monthly interviewed the gene editing technology CRISPR discoverer Zhang Feng, to discuss the technology's challenges, future applications and direction of development and other issues.
-
One hour results! Zhang Feng team released CRISPR detection technology of new coronavirus
Time of Update: 2020-02-18
Author: the novel coronavirus (COVID-19) outbreak of Gu Lulu has brought great challenges to global health In support of the war, "epidemic", on February 14, the broad Institute of Massachusetts Insti